Sugi Predict

Sugi Predict / Compounds / SCHEMBL2347880

SCHEMBL2347880

SCHEMBL2347880

Fc1ccc(-c2cnc3ccccc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 5/20 0.66
▸ PDGFRA P16234 5/20 0.66
▸ CA12 O43570 1/20 0.59
▸ CA1 P00915 1/20 0.59
▸ CA2 P00918 1/20 0.59
▸ CA9 Q16790 1/20 0.59
▸ PIK3CD O00329 3/20 0.58
▸ PIK3CA P42336 3/20 0.58
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ CYP2A6 P11509 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ BIRC5 O15392 1/20 0.56
▸ MTOR P42345 2/20 0.54
▸ PIK3CB P42338 1/20 0.50
▸ PIK3CG P48736 1/20 0.50
▸ TDP2 O95551 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ CSNK1G2 P78368 1/20 0.49
▸ CLK4 Q9HAZ1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378174 1.00 PDGFRB (0.66) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26548412 0.95 PDGFRB (0.60) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26547991 0.95 PDGFRB (0.60) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26549364 0.93 PDGFRB (0.58) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26548915 0.93 PDGFRB (0.58) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26549071 0.93 PDGFRB (0.58) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26548595 0.93 PDGFRB (0.58) PDGFRBPDGFRACA12CA1CA2
Quinoline SCHEMBL28787459 0.92 PDGFRB (0.61) PDGFRBPDGFRACA12CA1CA2
SCHEMBL24621829 0.86 PDGFRB (0.72) PDGFRBPDGFRACA12CA1CA2
SCHEMBL29375510 0.86 PDGFRB (0.72) PDGFRBPDGFRACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116655529-A Method for synthesizing 3-aryl quinoline compound by nickel catalysis 湖南大学 2023-08-29 — — CN disclosed
EP-2655382-B1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2022-09-28 — — EP disclosed
CN-108586500-B Zinc coordination complex and method for preparing organic zinc reagent 慕尼黑路德维希马克西米利安斯大学 2021-06-25 — — CN disclosed
CN-108586500-A Zinc co-ordination complex and the method for preparing organic zinc reagent 慕尼黑路德维希马克西米利安斯大学 2018-09-28 — — CN disclosed
CN-107312009-A Quinolines, its preparation method, intermediate, pharmaceutical composition and application 上海医药集团股份有限公司 2017-11-03 — — CN disclosed
CN-104109166-B Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof 上海医药集团股份有限公司 2017-06-20 — — CN disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 — — US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 — — US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 — — US disclosed
US-9193728-B2 Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-11-24 — — US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 — — US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 — — US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 — — US disclosed
EP-2655382-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME Ludwig-Maximilians-Universität München (DE) 2013-10-30 — — EP disclosed
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-15 — — US disclosed
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-15 — — US disclosed
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-15 — — US disclosed
WO-2012085168-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2012-06-28 — — WO disclosed
WO-2011103460-A1 FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2011-08-25 — — WO disclosed
CN-102070520-A Method for preparing 3-aryl-subsituted quinoline by 3-oxo-2,3-diarylpropionaldehyde UNIV EAST CHINA NORMAL 2011-05-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME ODC1, AOC1, ADH1C PDGFRB 1422/4885PDGFRA 2010/4885CA12 1323/4885
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR4, HTR3B, HTR2C PDGFRB 928/4885PDGFRA 1623/4885CA12 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.